More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Maya Desai
Advertisement
Articles by Maya Desai
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products.
Advertisement
Latest Updated Articles
- New Standards for First-to-Launch Players
September 14th 2020
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
What Governance Resets Should Pharma Companies Take in Response to AI?
3
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5